Vanda Pharmaceuticals Challenges FDA Proposal to Extend Drug Review Timelines
Event summary
- Vanda Pharmaceuticals opposes an FDA proposal to remove the 180-day statutory review requirement for new drug applications (NDAs), replacing it with longer PDUFA/GDUFA performance goals.
- The proposal would extend typical review times from 180 days to 10-12 months, including a two-month initial filing review period.
- Vanda argues the FDA is seeking to legalize its current practice of exceeding statutory timelines, which has been ruled unlawful by federal courts.
- The proposal also aims to replace formal evidentiary hearings with internal streamlined appeals, despite recent court rulings favoring Vanda's right to hearings.
- Vanda urges FDA Commissioner Dr. Marty Makary to withdraw the proposal and calls on Congress to reject it.
The big picture
Vanda's challenge highlights a broader tension between regulatory efficiency and bureaucratic inertia in drug approval processes. The FDA's proposal, if implemented, would formalize longer review times, potentially slowing innovation in an industry where speed-to-market is critical. This comes amid ongoing debates about balancing patient access with rigorous drug safety standards, with small innovators like Vanda often bearing the brunt of regulatory delays.
What we're watching
- Regulatory Dynamics
- Whether the FDA will withdraw the proposal or Congress will reject it, given Vanda's legal victories and the agency's stated goals for efficiency.
- Innovation Impact
- How extended review times could affect small biopharmaceutical innovators' financial risk and ability to bring new drugs to market.
- Governance Shifts
- The pace at which the FDA may adopt more transparent processes following Vanda's successful litigation for formal hearings.